Salgia Summarizes the Benefits of Tepotinib in MET Exon 14–Mutated NSCLC
Season 11, Episode 8, Sep 02, 06:00 PM
Dr Salgia discusses how he chooses between tepotinib and capmatinib in patients with stage IV NSCLC harboring MET exon 14 skipping mutations.